Pancreatic Calcium Handling in Islet Beta Cells in Patients With Type 1 Diabetes Mellitus (Pancreas MEMRI)

University of Edinburgh

Status: Completed

Conditions: Type 1 Diabetes

Study type: Observational

Funder types: Other

Identifiers

NCT05298735

AC20142

Details and patient eligibility

About

Approximately 400,000 people are living with type 1 diabetes mellitus (T1DM) in the United Kingdom: one of the highest rates in the world. It is characterised by autoimmune loss of pancreatic beta cell mass leading to metabolic dysregulation, requiring lifelong insulin therapy. It is now recognised that there are micro-secretors of insulin and that preservation of insulin secretion in these cases is associated with decreased complications. Therefore, recent research has focussed on using immunomodulation to preserve pancreatic beta cell mass. Evaluation of novel therapies for T1DM requires reliable methods to measure beta-cell function, which is unattainable using traditional non-invasive imaging techniques. A new approach is manganese-enhanced magnetic resonance imaging (MEMRI). This proof-of-concept study was designed to investigate whether MEMRI can be used as a measure of beta-cell function in people with T1DM.

Enrollment: 35 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age >18 years
• No regular medications
• No known significant medical conditions

Exclusion criteria

• Inability to consent
• Renal failure (eGFR <30 mL/min/1.73 m2)
• Standard MRI contraindications
• Pregnancy or breast feeding

Trial design

35 participants in 2 patient groups

Healthy volunteers

Description:

Healthy volunteers with no known significant medical conditions

Patients with type 1 diabetes

Description:

Patients with a diagnosis of type 1 diabetes (with or without detectable C-peptide)